PATENT CLAIM ANALYSIS

Application Number: 16190869
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-03
Patent Classification: ["514", "312000"]

Abstract:
The invention relates to administration of various pharmaceutical formulations of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (cabozantinib) a c-Met inhibitor, and its metabolites, to achieve desirable pharmacokinetic and pharmacodynamic effects.

Claim (Index 4):
The pharmaceutical formulation of  claims 1 - 2 , wherein the measured metabolites comprise one or more of:

Metadata:
- Claim Count in Document: 15.0
- Percentile: 98.0
- Lexical Diversity: 1.28205
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15126767', '10706328', '14776337', '12845600', '13714246']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7578714052207433
- 35 USC 102 Novelty (BERT): 0.5927999693057314
- Combined Prediction Score: 0.7413642616292421
- Mean Citation Score: 328.67702799999995
- Max Citation Score: 562.41516
- Similarity Product: 390.5031130745745

Labels:
- Claim Label 101: 0
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test